Clinical trial · Observational
Timing of Renal Replacement Therapy Initiation in Tumor Lysis Syndrome
NCT06889974CI-TRIAL-00100512TENDERSrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The TENDERS study aims to evaluate the impact of the timing of renal replacement therapy (RRT) initiation on outcomes in patients with tumor lysis syndrome (TLS) and associated acute kidney injury (AKI). The study will compare early versus delayed RRT initiation, examining the effect on renal function at 30 days post-treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Renal Replacement Therapy for Acute Kidney Injury in ICU | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- Patients with early initiation of renal replacement therapy (RRT)
- description
- Patients with early initiation of RRT, RRT within 24 hours of acute kidney injury (AKI) diagnosis.
- label
- Patients with delayed initiation of RRT
- description
- Patients with delayed initiation of RRT, RRT initiated only after urgent clinical indications arise, such as severe hyperkalemia or metabolic acidosis.
Primary outcomes (1)
- measure
- Renal dysfunction at ICU discharge
- timeFrame
- From baseline to up to 30 days .
- description
- The primary outcome is renal dysfunction at ICU discharge, defined as a ≥25% increase in serum creatinine from baseline, assessed at the time of ICU discharge.
Secondary outcomes (7)
- measure
- Incidence of AKI
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adults aged ≥18 years. * Hospitalized in the ICU between January 1, 2013, and December 31, 2023. * Diagnosed with a hematologic malignancy or solid tumor requiring chemotherapy. * Diagnosed with TLS based on the presence of two or more biochemical criteria (e.g., hyperkalemia, hyperphosphatemia, hyperuricemia, hypocalcemia) within 3 days before or 7 days after chemotherapy initiation. Exclusion Criteria: * Patient or family opposition to data collection for research purposes. * Incomplete medical records that preclude data extraction.
References
Publications (0)
Data not yet available
No reference posted for this study.